{
    "clinical_study": {
        "@rank": "70727", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I. Determine the effectiveness of oral bile acid therapy with cholic acid,\n      chenodeoxycholic acid, and ursodeoxycholic acid in patients with peroxisomal disorders\n      involving impaired primary bile acid synthesis.\n\n      II. Determine whether suppression of synthesis of atypical bile acids and enrichment of bile\n      acid pool with this regimen is effective in treating this patient population and improving\n      quality of life."
        }, 
        "brief_title": "Study of Bile Acids in Patients With Peroxisomal Disorders", 
        "condition": [
            "Infantile Refsum's Disease", 
            "Zellweger Syndrome", 
            "Bifunctional Enzyme Deficiency", 
            "Adrenoleukodystrophy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Refsum Disease", 
                "Zellweger Syndrome", 
                "Adrenoleukodystrophy", 
                "Refsum Disease, Infantile", 
                "Peroxisomal Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients receive oral cholic acid and oral chenodeoxycholic acid on day 1.\n      On day 4, patients receive oral cholic and ursodeoxycholic acids. Patients are assessed at 3\n      and 6 months for liver function response, neurologic status, and nutritional status.\n\n      Patients receive treatment until disease progression or unacceptable toxic effects are\n      observed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Biochemically proven peroxisomal disorder, including:\n\n          -  Zellweger syndrome\n\n          -  Pseudo-Zellweger syndrome\n\n          -  Neonatal adrenoleukodystrophy\n\n          -  Bifunctional enzyme deficiency\n\n          -  Infantile Refsum's disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "5 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "25", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004442", 
            "org_study_id": "199/13442", 
            "secondary_id": "CHMC-C-FDR000995"
        }, 
        "intervention": [
            {
                "intervention_name": "chenodeoxycholic acid", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "cholic acid", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "ursodiol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chenodeoxycholic Acid", 
                "Cholic Acids", 
                "Ursodeoxycholic Acid"
            ]
        }, 
        "keyword": [
            "Zellweger syndrome", 
            "adrenoleukodystrophy", 
            "bifunctional enzyme deficiency", 
            "inborn errors of metabolism", 
            "infantile Refsum's disease", 
            "peroxisomal disorders", 
            "pseudo-Zellweger syndrome", 
            "rare disease", 
            "sphingolipidoses"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_contact": {
            "last_name": "Kenneth Setchell", 
            "phone": "513-636-4548"
        }, 
        "overall_official": {
            "affiliation": "Children's Hospital Medical Center, Cincinnati", 
            "last_name": "Kenneth Setchell", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004442"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Children's Hospital Medical Center, Cincinnati", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2000"
    }, 
    "geocoordinates": {}
}